Comunicado de la FDA sobre la seguridad de los medicamentos: Estudio de la FDA de pacientes de Medicare encontr ó menor riesgo de derrame cerebral y muerte con Pradaxa (dabigatrán) en comparación con warfarina
[05-13-2014] En su estudio en curso del anticoagulante Pradaxa (dabigatr án), la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus sigla en inglés) completó recientemente un nuevo estudio en pacientes de Medicare en el que compara Pradaxa con un anticoagulante antiguo, warfarina (Coumadin, Jantoven y genéricos), para determinar el riesgo de a ccidente isquémico o derrame causado por un coágulo, hemorragia cerebral, hemorragia gastrointestinal severa, infarto de miocardio y muerte. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin
[05-13-2014] In its ongoing review of the blood thinner Pradaxa (dabigatran), the U.S. Food and Drug Administration (FDA) recently completed a new study in Medicare patients comparing Pradaxa to an older blood thinner, warfarin, for risk of ischemic or clot-related stroke, bleeding in the brain, major gastrointestinal (GI) bleeding, myocardial infarction (MI), and death. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves
The U.S. Food and Drug Administration (FDA) is informing health care professionals and the public that the blood thinner (anticoagulant) Pradaxa (dabigatran etexilate mesylate) should not be used to prevent stroke or blood clots (major thromboembolic events) in patients with mechanical heart valves, also known as mechanical prosthetic heart valves. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 13, 2018 Category: Drugs & Pharmacology Source Type: news
Dabigatran vs warfarin in NVAF: ERG risk score predicts cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2018 Category: Drugs & Pharmacology Source Type: news
Novel Antithrombotics and Lower Risk of Intraocular Bleeding Novel Antithrombotics and Lower Risk of Intraocular Bleeding
Novel antithrombotics such as dabigatran or rivaroxaban are associated, in some instances, with a decreased risk of intraocular hemorrhage compared with traditional anticoagulant therapy.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Will new pill to stop a clot save me from a stroke?
I have recently been prescribed Pradaxa to prevent clots and have been told there is a 3 per cent chance of me having a stroke. Is this a high risk, asks Lionel Jenkins, New Zealand (Source: the Mail online | Health)
Source: the Mail online | Health - December 18, 2017 Category: Consumer Health News Source Type: news
Real-world Study Reassures on Dabigatran Stroke, ICH Rates Real-world Study Reassures on Dabigatran Stroke, ICH Rates
But results confirm gastrointestinal bleeding risk, particularly in the elderly and those with renal failure, and questions over the MI risk still remain.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 29, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa ® (dabigatran etexilate) litigation
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Antidote for rapid reversal of Pradaxa ® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
As the benefits and safety of Pradaxa ® (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa to help more patients
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New data analyses show consistent efficacy and safety profile of Pradaxa ® in broad range of patients with acute deep vein thrombosis or pulmonary embolism*
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Application submitted to the European Medicines Agency (EMA) for use of Pradaxa ® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
New Data for Pradaxa ® and Praxbind® at AHA Scientific Sessions 2017
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Pradaxa ®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
U.S. FDA grants Breakthrough Therapy Designation to Pradaxa ®
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
